IL2 and myelodysplastic syndrome: In a Phase I trial, the recurrence of myeloid malignancies (AML, MDS, MDS/MPN, or blastic plasmacytoid dendritic cell neoplasm (BPDC)) post-haploidentical HCT was addressed with lymphodepleting chemotherapy followed by the infusion of donor-derived CIML NK cells at a dosage ranging from 5 to 10 × 106 cells/kg, along with IL-2 administration.